PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1792844
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1792844
Global Skin Hives Treatment Market to Reach US$4.4 Billion by 2030
The global market for Skin Hives Treatment estimated at US$2.9 Billion in the year 2024, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Chronic Hives, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Acute Hives segment is estimated at 5.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$785.8 Million While China is Forecast to Grow at 11.7% CAGR
The Skin Hives Treatment market in the U.S. is estimated at US$785.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$939.0 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
Global Skin Hives Treatment Market - Key Trends & Drivers Summarized
Why Is the Management of Skin Hives Evolving From Symptom Control to Etiology-Specific Approaches?
Skin hives, or urticaria, are transient eruptions characterized by raised, itchy welts resulting from histamine release in the dermis. Historically managed with first-generation antihistamines and topical steroids, treatment paradigms for hives have shifted toward targeted, evidence-based protocols that distinguish between acute (lasting less than six weeks) and chronic (lasting six weeks or more) forms. This shift is being driven by a growing understanding of immunological mechanisms, such as autoantibodies, mast cell hypersensitivity, and external triggers like infections, allergens, or stress. As chronic urticaria becomes more prevalent, particularly in urban, high-stress populations, dermatologists and allergists are increasingly adopting stepwise treatment algorithms involving newer-generation therapies.
Acute hives typically resolve with non-sedating H1-antihistamines like cetirizine, loratadine, or fexofenadine. However, chronic spontaneous urticaria (CSU) and inducible urticaria require escalation to higher antihistamine doses, H2 blockers, leukotriene antagonists (montelukast), or biologics such as omalizumab (anti-IgE monoclonal antibody). This movement toward precision management is improving symptom control and reducing recurrence. Additionally, the use of diagnostic tools such as autologous serum skin tests (ASST), patch testing, and basophil activation tests is supporting individualized treatment and identifying refractory or autoimmune-driven cases.
How Are Biologics and Targeted Therapies Reshaping the Treatment Landscape?
Biologics are revolutionizing chronic urticaria treatment, particularly for patients unresponsive to antihistamines. Omalizumab, originally developed for asthma, has shown strong efficacy in CSU, reducing flare frequency and improving quality of life. It works by binding to free IgE, thereby preventing activation of mast cells and basophils. Its use is now recommended in step 3 of urticaria treatment guidelines by EAACI/GA²LEN/WAO. Ongoing clinical trials are investigating other biologics-such as dupilumab (IL-4 receptor inhibitor) and ligelizumab (a next-gen anti-IgE antibody)-to target downstream inflammatory pathways more precisely.
The appeal of biologics lies in their favorable side effect profiles, long dosing intervals, and rapid action. However, high costs and limited access remain barriers in many low- and middle-income countries. To address this, biosimilars and subcutaneous formulations with better affordability and administration convenience are being developed. Parallel efforts in repurposing immunomodulators like cyclosporine A for severe CSU are extending treatment options, especially in settings with limited biologics access.
In the over-the-counter segment, formulations containing antihistamines, calamine, aloe vera, and menthol are being optimized for faster onset and longer-lasting relief. Topical delivery systems-such as transdermal patches and lipid-based creams-are being engineered to enhance skin penetration while minimizing systemic absorption. These innovations are expanding the therapeutic arsenal for patients with mild or transient hives seeking immediate symptom control without systemic medication.
Which Patient Demographics and Environmental Factors Are Influencing Treatment Demand?
Urticaria affects individuals of all ages, but chronic forms are more commonly reported among adults aged 20-50, with a notable prevalence among women. Hormonal changes, autoimmune predispositions, and stress-related triggers contribute to gender and age-related disease patterns. Pediatric urticaria is often acute, related to viral infections, food allergies, or vaccines, and is typically managed with weight-adjusted antihistamines and avoidance strategies. The need for child-friendly liquid formulations and non-drowsy options is driving innovation in pediatric hives treatment products.
Urbanization, pollution, and climate variability are also contributing to hives outbreaks. Airborne allergens, food additives, UV exposure, and thermal changes are increasingly recognized as triggers, especially for chronic inducible urticaria. In industrialized nations, rising awareness and early diagnosis are translating into higher prescription volumes for both first-line and advanced therapies. Conversely, in emerging markets, underdiagnosis, lack of insurance coverage, and preference for traditional remedies are influencing care-seeking behavior and limiting access to modern treatments.
Psychodermatological correlations-such as anxiety, sleep disruption, and depression-are gaining recognition in chronic urticaria cases. As a result, integrative care models combining dermatology with behavioral health are being piloted, especially in tertiary centers. Lifestyle management strategies, including stress reduction, elimination diets, and allergen avoidance, are increasingly recommended alongside pharmacotherapy to address root causes and reduce flare frequency.
What Forces Are Driving Global Growth in the Skin Hives Treatment Market?
The growth in the global skin hives treatment market is driven by several factors including the rising incidence of chronic urticaria, expanded biologic approvals, and growing awareness of allergy-related skin disorders. Global lifestyle changes, increasing pollution, and dietary additives are contributing to higher disease prevalence, particularly in urban environments. Concurrently, improved patient education and dermatologist outreach campaigns are enabling earlier diagnosis and intervention.
Market expansion is also being fueled by advancements in dermatology-focused telehealth, e-pharmacy access to antihistamines, and the inclusion of hives treatment in digital health applications. These platforms are enabling prescription renewals, flare tracking, and symptom diaries-improving long-term disease monitoring and treatment compliance. Insurance coverage of biologics in high-income regions and expanded regulatory approval pipelines are making advanced therapies accessible to more patients.
The market is also witnessing significant activity from pharmaceutical manufacturers developing next-generation monoclonal antibodies, topical delivery platforms, and dual-action antihistamines. Consumer brands are leveraging botanicals, colloidal oatmeal, and herbal antihistamines in clean-label OTC products targeting mild hives relief. With dermatological awareness, biological innovation, and personalized treatment protocols continuing to evolve, the skin hives treatment market is positioned for robust and sustained global expansion.
SCOPE OF STUDY:
The report analyzes the Skin Hives Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Chronic Hives, Acute Hives); Treatment (Anti-Inflammatory Drugs Treatment, Anti-Itch Drugs Treatment, Antihistamines Treatment, Other Treatments); Administration Route (Oral Administration, Topical Administration, Parenteral Administration); Distribution Channel (Hospital Pharmacies, Online Distribution Channel, Retail Pharmacies)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 42 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.